Andrew Saxon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Saxon has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Ke Zhang
6 shared publicationsDaocheng Zhu
3 shared publicationsChristopher L Kepley
2 shared publicationsAnne Behnecke
1 shared publicationChris Kepley
1 shared publication- Christopher L Kepley
Department of Internal Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA
1 shared publication
Latest Publications
- 1 February 2013
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 131 (2) , AB95
Prevention and Treatment of Poly-Lysine Modified Arah2 DNA Vaccine On Arah2 Protein Induced Allergy
- 1 February 2013
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 131 (2) , AB95
Prevention and Treatment of Poly-Lysine Modified Arah2 DNA Vaccine On Arah2 Protein Induced Allergy
- 1 February 2008
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 121 (2) , 320-325
“Accentuate the negative, eliminate the positive”: Engineering allergy therapeutics to block allergic reactivity through negative signaling
- 1 February 2008
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 121 (2) , 320-325
“Accentuate the negative, eliminate the positive”: Engineering allergy therapeutics to block allergic reactivity through negative signaling
- 15 June 2006
- Published by Elsevier in Clinical Immunology
- Vol. 120 (2) , 237
Book Review | Epstein Barr Virus, Alex Tselis, Hal B. Jenson (Eds.), Taylor and Francis (2006), List Price: $189.95. Cat. #: DK2152., 432 pp., ISBN: 0824754255
- 15 June 2006
- Published by Elsevier in Clinical Immunology
- Vol. 120 (2) , 237
Book Review | Epstein Barr Virus, Alex Tselis, Hal B. Jenson (Eds.), Taylor and Francis (2006), List Price: $189.95. Cat. #: DK2152., 432 pp., ISBN: 0824754255
- Open Access
- 1 June 2006
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 114 (6) , A338
Exposure to a Fungal Volatile Compound: Significance of Effects
- 1 June 2006
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 114 (6) , A338
Open AccessExposure to a Fungal Volatile Compound: Significance of Effects
- 1 January 2006
- No. 95,p. 223
Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.
This review summarizes current knowledge regarding the control of human mast cell and basophil signaling and recent developments using a new therapeutic platform consisting of a human bifunctional gamma and epsilon heavy chain (Fcgamma-Fcepsilon) protein to inhibit allergic reactivity. Crosslinking of FcgammaRIIb to FcepsilonRI on human mast cells and basophils by a genetically engineered Fcgamma-Fcepsilon protein (GE2) leads to the inhibition of mediator release upon FcepsilonRI challenge. GE2 protein was shown to inhibit cord blood-derived mast cell and peripheral blood basophil mediator release in vitro in a dose dependent fashion including inhibition of human IgE reactivity to cat. In addition, IgE-mediated release from lung tissue was inhibited through GE2. The mechanism of inhibition in mast cells included alterations in IgE-mediated Ca2+ mobilization, Syk phosphorylation and the formation of Dok-Grb2-SHIP complex. Proallergic effects of Langerhans-like dendritic cells and B cell IgE switching were also inhibited by GE2. In vivo, GE2 was shown to block passive cutaneous anaphylaxis (PCA) driven by human IgE in mice expressing the human FcepsilonRI and inhibit skin test reactivity to dust mite antigen in a dose dependent manner in rhesus monkeys. The balance between positive and negative signaling controls mast cell and basophil reactivity that is critical in the expression of human allergic diseases. This approach using a human Fcgamma-Fcepsilon fusion protein to co-aggregate FcepsilonRI with the FcgammaRII holds promise as a new therapeutic platform for the immunomodulation of allergic diseases and potentially other mast cell/basophil-dependent disease states.
- 1 January 2006
- No. 95,p. 223
Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.
This review summarizes current knowledge regarding the control of human mast cell and basophil signaling and recent developments using a new therapeutic platform consisting of a human bifunctional gamma and epsilon heavy chain (Fcgamma-Fcepsilon) protein to inhibit allergic reactivity. Crosslinking of FcgammaRIIb to FcepsilonRI on human mast cells and basophils by a genetically engineered Fcgamma-Fcepsilon protein (GE2) leads to the inhibition of mediator release upon FcepsilonRI challenge. GE2 protein was shown to inhibit cord blood-derived mast cell and peripheral blood basophil mediator release in vitro in a dose dependent fashion including inhibition of human IgE reactivity to cat. In addition, IgE-mediated release from lung tissue was inhibited through GE2. The mechanism of inhibition in mast cells included alterations in IgE-mediated Ca2+ mobilization, Syk phosphorylation and the formation of Dok-Grb2-SHIP complex. Proallergic effects of Langerhans-like dendritic cells and B cell IgE switching were also inhibited by GE2. In vivo, GE2 was shown to block passive cutaneous anaphylaxis (PCA) driven by human IgE in mice expressing the human FcepsilonRI and inhibit skin test reactivity to dust mite antigen in a dose dependent manner in rhesus monkeys. The balance between positive and negative signaling controls mast cell and basophil reactivity that is critical in the expression of human allergic diseases. This approach using a human Fcgamma-Fcepsilon fusion protein to co-aggregate FcepsilonRI with the FcgammaRII holds promise as a new therapeutic platform for the immunomodulation of allergic diseases and potentially other mast cell/basophil-dependent disease states.
- 30 November 2005
- Published by Elsevier in Clinical Immunology
- Vol. 117 (2) , 193
Editor's note
- 27 March 2005
- Published by Springer Nature in Nature Medicine
- Vol. 11 (4) , 446-449
A chimeric human-cat fusion protein blocks cat-induced allergy
Animal allergens are an important cause of asthma and allergic rhinitis. We designed and tested a chimeric human-cat fusion protein composed of a truncated human IgG Fcgamma1 and the major cat allergen Fel d1, as a proof of concept for a new approach to allergy immunotherapy. This Fcgamma-Fel d1 protein induced dose-dependent inhibition of Fel d1-driven IgE-mediated histamine release from cat-allergic donors' basophils and sensitized human cord blood-derived mast cells. Such inhibition was associated with altered Syk and ERK signaling. The Fcgamma-Fel d1 protein also blocked in vivo reactivity in FcepsilonRIalpha transgenic mice passively sensitized with human IgE antibody to cat and in Balb/c mice actively sensitized against Fel d1. The Fcgamma-Fel d1 protein alone did not induce mediator release. Chimeric human Fcgamma-allergen fusion proteins may provide a new therapeutic platform for the immune-based therapy of allergic disease.
- 27 March 2005
- Published by Springer Nature in Nature Medicine
- Vol. 11 (4) , 446-449
A chimeric human-cat fusion protein blocks cat-induced allergy
Animal allergens are an important cause of asthma and allergic rhinitis. We designed and tested a chimeric human-cat fusion protein composed of a truncated human IgG Fcgamma1 and the major cat allergen Fel d1, as a proof of concept for a new approach to allergy immunotherapy. This Fcgamma-Fel d1 protein induced dose-dependent inhibition of Fel d1-driven IgE-mediated histamine release from cat-allergic donors' basophils and sensitized human cord blood-derived mast cells. Such inhibition was associated with altered Syk and ERK signaling. The Fcgamma-Fel d1 protein also blocked in vivo reactivity in FcepsilonRIalpha transgenic mice passively sensitized with human IgE antibody to cat and in Balb/c mice actively sensitized against Fel d1. The Fcgamma-Fel d1 protein alone did not induce mediator release. Chimeric human Fcgamma-allergen fusion proteins may provide a new therapeutic platform for the immune-based therapy of allergic disease.
- 31 January 2005
- Published by Elsevier in Clinical Immunology
- Vol. 114 (1) , 1
Onward and upward
- 1 December 2004
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 4 (6) , 563-568
Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases
This review summarizes current knowledge regarding the control of human mast cell and basophil signaling and recent developments using a new therapeutic platform consisting of a human bifunctional γ and ε heavy chain (Fcγ-Fcε) protein to inhibit allergic reactivity. Crosslinking of FcγRIIb to FcεRI on human mast cells and basophils by a genetically engineered Fcγ-Fcε protein (GE2) leads to the inhibition of mediator release upon FcεRI challenge. GE2 protein was shown to inhibit cord blood-derived mast cell and peripheral blood basophil mediator release in vitro in a dose-dependent fashion, including inhibition of human IgE reactivity to cat. IgE-driven mediator release from lung tissue was also inhibited by GE2. The mechanism of inhibition in mast cells included alterations in IgE-mediated Ca2+ mobilization, spleen tyrosine kinase phosphorylation and the formation of downstream of kinase-growth factor receptor-bound protein 2-SH2 domain-containing inositol 5-phosphatase (dok-grb2-SHIP) complexes. Proallergic effects of Langerhan's like dendritic cells and B-cell IgE switching were also inhibited by GE2. In vivo, GE2 was shown to block passive cutaneous anaphylaxis driven by human IgE in mice expressing the human FcεRI and inhibit skin test reactivity to dust mite antigen in a dose-dependent manner in rhesus monkeys. The balance between positive and negative signaling controls mast cell and basophil reactivity, which is critical in the expression of human allergic diseases. This approach using a human Fcγ-Fcε fusion protein to co-aggregate FcεRI with the FcγRII holds promise as a new therapeutic platform for the immunomodulation of allergic diseases and potentially other mast cell/basophil-dependent disease states.
- 1 December 2004
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 4 (6) , 563-568
Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases
This review summarizes current knowledge regarding the control of human mast cell and basophil signaling and recent developments using a new therapeutic platform consisting of a human bifunctional γ and ε heavy chain (Fcγ-Fcε) protein to inhibit allergic reactivity. Crosslinking of FcγRIIb to FcεRI on human mast cells and basophils by a genetically engineered Fcγ-Fcε protein (GE2) leads to the inhibition of mediator release upon FcεRI challenge. GE2 protein was shown to inhibit cord blood-derived mast cell and peripheral blood basophil mediator release in vitro in a dose-dependent fashion, including inhibition of human IgE reactivity to cat. IgE-driven mediator release from lung tissue was also inhibited by GE2. The mechanism of inhibition in mast cells included alterations in IgE-mediated Ca2+ mobilization, spleen tyrosine kinase phosphorylation and the formation of downstream of kinase-growth factor receptor-bound protein 2-SH2 domain-containing inositol 5-phosphatase (dok-grb2-SHIP) complexes. Proallergic effects of Langerhan's like dendritic cells and B-cell IgE switching were also inhibited by GE2. In vivo, GE2 was shown to block passive cutaneous anaphylaxis driven by human IgE in mice expressing the human FcεRI and inhibit skin test reactivity to dust mite antigen in a dose-dependent manner in rhesus monkeys. The balance between positive and negative signaling controls mast cell and basophil reactivity, which is critical in the expression of human allergic diseases. This approach using a human Fcγ-Fcε fusion protein to co-aggregate FcεRI with the FcγRII holds promise as a new therapeutic platform for the immunomodulation of allergic diseases and potentially other mast cell/basophil-dependent disease states.